Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

Published:2016-07-25 Issue:12 Volume:19 Page:1144-1156
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Virabhak Suchin¹,Yasui Kikuo²,Yamazaki Kiyotaka²,Johnson Scott¹,Mitchell Dominic¹,Yuen Cammy³,Samp Jennifer C.⁴,Igarashi Ataru⁵

Affiliation:

1. Medicus Economics LLC, Milton, MA, USA;

2. AbbVie GK, Minato-ku, Tokyo, Japan;

3. Abbvie Pte. Ltd., Singapore, Singapore;

4. AbbVie Inc., Mettawa, IL, USA;

5. Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

Funder

AbbVie

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1206908

Reference53 articles.

1. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

2. Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan

3. Global epidemiology and genotype distribution of the hepatitis C virus infection

4. Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearance;World Journal of Clinical Cases;2023-08-06

2. Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearance;World Journal of Clinical Cases;2023-08-06

3. Role of liver stiffness measurements in patients who develop hepatocellular carcinoma after clearance of the hepatitis C virus;Journal of Medical Ultrasonics;2022-02-07

4. Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages;PLOS ONE;2021-04-01

5. Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia;Value in Health Regional Issues;2020-05